Ken Griffin Kronos Bio, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 51,200 shares of KRON stock, worth $35,840. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,200

Previous 10,000 412.0%

Holding current value

$35,840

Previous $9,000 355.56%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.82 - $1.07 $81,598 - $106,475	99,510 Added 114.12%	186,711 $177,000
Q3 2024 Nov 14, 2024	SELL	$0.92 - $1.5 $129,407 - $210,990	-140,660 Reduced 61.73%	87,201 $87,000
Q2 2024 Aug 14, 2024	BUY	$0.73 - $1.38 $28,069 - $53,063	38,452 Added 20.3%	227,861 $282,000
Q1 2024 May 15, 2024	SELL	$1.02 - $1.3 $8,722 - $11,116	-8,551 Reduced 4.32%	189,409 $246,000
Q4 2023 Feb 14, 2024	BUY	$0.75 - $1.49 $33,460 - $66,474	44,614 Added 29.09%	197,960 $247,000
Q3 2023 Nov 14, 2023	SELL	$1.23 - $2.25 $75,214 - $137,587	-61,150 Reduced 28.51%	153,346 $199,000
Q2 2023 Aug 14, 2023	BUY	$1.24 - $1.92 $159,349 - $246,735	128,508 Added 149.45%	214,496 $368,000
Q1 2023 May 15, 2023	SELL	$1.34 - $2.62 $168,329 - $329,121	-125,619 Reduced 59.36%	85,988 $125,000
Q4 2022 Feb 14, 2023	SELL	$1.44 - $3.44 $339,373 - $810,725	-235,676 Reduced 52.69%	211,607 $342,000
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $1.46 Million - $2.42 Million	-436,073 Reduced 49.37%	447,283 $1.5 Million
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $660,663 - $1.59 Million	211,751 Added 31.53%	883,356 $3.22 Million
Q1 2022 May 16, 2022	SELL	$6.26 - $14.42 $113,975 - $262,544	-18,207 Reduced 2.64%	671,605 $4.86 Million
Q4 2021 Feb 14, 2022	SELL	$11.35 - $21.18 $136,846 - $255,367	-12,057 Reduced 1.72%	689,812 $9.37 Million
Q3 2021 Nov 15, 2021	SELL	$18.17 - $24.7 $1.19 Million - $1.62 Million	-65,739 Reduced 8.56%	701,869 $14.7 Million
Q2 2021 Aug 16, 2021	SELL	$20.08 - $29.02 $1.64 Million - $2.36 Million	-81,440 Reduced 9.59%	767,608 $18.4 Million
Q1 2021 May 17, 2021	SELL	$27.0 - $32.48 $2.26 Million - $2.72 Million	-83,837 Reduced 8.99%	849,048 $24.9 Million
Q4 2020 Feb 16, 2021	BUY	$26.68 - $38.23 $24.9 Million - $35.7 Million	932,885 New	932,885 $27.9 Million

Others Institutions Holding KRON

# of Institutions

Shares Held

19.4M

Call Options Held

51.2K

Put Options Held

View Full List

About Kronos Bio, Inc.

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $39.7M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

More about KRON

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account